
Please try another search
Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in Phase II clinical trials to treat non-small cell lung cancer. Curasight A/S was incorporated in 2013 and is based in Copenhagen, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Ulrich Alexander Krasilnikoff | 58 | 2016 | CEO, CFO & Executive Director |
Lars Trolle | 58 | 2014 | Independent Deputy Chairman of the Board |
Charlotte Vedel | 57 | 2020 | Independent Director |
Kirsten Aarup Drejer | 69 | 2021 | Chairman of the Board |
Andreas Kjaer | 62 | 2013 | Co-Founder, Chief Scientific Officer, Chief Medical Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review